



an Open Access Journal by MDPI

## Precision Medicine in Gastrointestinal Neoplasms

Guest Editors:

### Dr. Juan Torres-Melero

Peritoneal Oncology Surgery  
Unit, Torrecárdenas University  
Hospital, 04009 Almería, Spain

### Dr. María Jose Serrano

1. Medical and Radiotherapeutic  
Unit, University Hospital Virgen  
de las Nieves, Avenida de la  
Ilustración, 114-18016 Granada,  
Spain  
2. Liquid Biopsy and Cancer  
Interception Group, GENYO,  
Centre for Genomics and  
Oncological Research, Pfizer-  
University of Granada-Andalusian  
Regional Government, PTS  
Granada, Avenida de la  
Ilustración 114, 18016 Granada,  
Spain

Deadline for manuscript  
submissions:

**25 April 2025**

### Message from the Guest Editors

Precision medicine in gastrointestinal malignancies represents an innovative and highly specialized approach to cancer treatment. This paradigm focuses on personalizing treatment based on the specific genetic and molecular characteristics of each patient's tumor, as well as other individual factors. The focus of this Special Issue is on, but not limited to, the following:

1. Tumor genomics or DNA sequencing
2. Biomarkers: predictive or prognostic
3. Targeted therapies
4. Immunotherapy.

Moreover, some challenges we are currently facing that should be clarified in the near future include the following:

1. Accessibility and Cost: Genetic testing and targeted therapies can be expensive and are not always covered by insurance.
2. Continuous Research: Need for clinical studies that validate new therapies and combinations.
3. Liquid Biopsies: Development of noninvasive methods for monitoring tumor evolution and response to treatment.

In summary, precision medicine in gastrointestinal malignancies promises to significantly improve treatment outcomes by tailoring interventions to each patient's unique characteristics, thereby reducing side effects and increasing treatment efficacy.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)